<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146326">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01946386</url>
  </required_header>
  <id_info>
    <org_study_id>LP0053-69</org_study_id>
    <nct_id>NCT01946386</nct_id>
  </id_info>
  <brief_title>A Vasoconstriction Study With LEO 90100</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <authority>France: ANSM - Agence Nationale de Sécurité du Médicaments et des Produits de Santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacodynamic activity of LEO 90100 with
      Dermovate® cream, Dovobet® ointment, betamethasone dipropionate in LEO90100 vehicle,
      Synalar® ointment and LEO 90100 vehicle using a human skin blanching test.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual assessment of skin blanching (visual score (VS))</measure>
    <time_frame>06:10, 08:00, 10:00, 12:00, 24:00, 28:00 and 32:00 hours after application</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual Assessment of Skin Blanching on scores 0 to 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in colorimetric parameter a* (the red/green balance) at each time point</measure>
    <time_frame>06:10, 08:00, 10:00, 12:00, 24:00, 28:00 and 32:00 hours after application</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in colorimetric parameter. AUC (0-32h) of this change by treatment site will be calculated after subtraction of untreated site change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in colorimetric parameter L* (luminance) at each time point (ΔL*)</measure>
    <time_frame>06:10, 08:00, 10:00, 12:00, 24:00, 28:00 and 32:00 hours after application</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC (0-32h) of this change by treatment site will be calculated after subtraction of untreated site change</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 90100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Not applicable</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 90100 Aerosol, foam</intervention_name>
    <description>The products will be applied on 6 test sites (according to random assignment to specific test sites predetermined on their anterior face of forearms) for 6 hours</description>
    <arm_group_label>LEO 90100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle</intervention_name>
    <arm_group_label>LEO 90100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 90100 Aerosol, foam, vehicle</intervention_name>
    <arm_group_label>LEO 90100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daivobet® ointment</intervention_name>
    <arm_group_label>LEO 90100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dermovate® cream</intervention_name>
    <arm_group_label>LEO 90100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Synalar® ointment</intervention_name>
    <arm_group_label>LEO 90100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Following verbal and written information about the trial, the subject must provide
             signed and dated informed consent before any study related activities are carried
             out.

          -  Healthy male or female volunteers, 18 to 50 years old, both inclusive

        Exclusion Criteria:

          -  Female subjects who are pregnant or who are breast feeding.

          -  Abnormal pigmentation of the skin or skin type that could, in any way, confound
             interpretation of the study results (skin type V and VI on the Fitzpatrick scale)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CPCAD, Centre de Pharmacologie Clinique Appliquée à la Dermatologie</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 24, 2013</lastchanged_date>
  <firstreceived_date>September 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Clobetasol</mesh_term>
    <mesh_term>Fluocinolone Acetonide</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
